Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
17 analysts have shared their evaluations of Colgate-Palmolive (NYSE:CL) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 8 | 3 | 6 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 1 | 0 | 0 | 0 | 0 |
2M Ago | 5 | 2 | 4 | 0 | 0 |
3M Ago | 2 | 1 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $106.0, a high estimate of $122.00, and a low estimate of $91.00. Surpassing the previous average price target of $100.67, the current average has increased by 5.29%.
A clear picture of Colgate-Palmolive's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Steve Powers | Deutsche Bank | Raises | Hold | $109.00 | $107.00 |
Peter Grom | UBS | Raises | Buy | $122.00 | $119.00 |
Robert Moskow | TD Cowen | Raises | Buy | $115.00 | $110.00 |
Callum Elliott | Bernstein | Raises | Market Perform | $103.00 | $100.00 |
Steve Powers | Deutsche Bank | Raises | Buy | $107.00 | $104.00 |
Dara Mohsenian | Morgan Stanley | Raises | Overweight | $111.00 | $103.00 |
Lauren Lieberman | Barclays | Raises | Equal-Weight | $96.00 | $91.00 |
Kaumil Gajrawala | Jefferies | Lowers | Hold | $95.00 | $103.00 |
Robert Moskow | TD Cowen | Announces | Buy | $110.00 | - |
Mark Astrachan | Stifel | Raises | Buy | $105.00 | $95.00 |
Lauren Lieberman | Barclays | Raises | Equal-Weight | $91.00 | $85.00 |
Robert Ottenstein | Evercore ISI Group | Raises | Outperform | $106.00 | $100.00 |
Steve Powers | Deutsche Bank | Raises | Buy | $104.00 | $98.00 |
Filippo Falorni | Citigroup | Raises | Buy | $112.00 | $103.00 |
Bryan Spillane | B of A Securities | Raises | Buy | $110.00 | $100.00 |
Chris Carey | Wells Fargo | Raises | Equal-Weight | $97.00 | $92.00 |
Kevin Grundy | Exane BNP Paribas | Announces | Outperform | $109.00 | - |
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Colgate-Palmolive's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Colgate-Palmolive analyst ratings.
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Colgate-Palmolive's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.89% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Consumer Staples sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Colgate-Palmolive's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.45% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Colgate-Palmolive's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 414.16%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Colgate-Palmolive's ROA excels beyond industry benchmarks, reaching 4.42%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 70.54, caution is advised due to increased financial risk.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CL